FUNCTIONS OF EBNA-1 IN THE STABLE REPLICATION OF EBV
EBNA-1在EBV稳定复制中的作用
基本信息
- 批准号:6653091
- 负责人:
- 金额:$ 14.89万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1999
- 资助国家:美国
- 起止时间:1999-09-30 至 2004-08-31
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
I will continue ongoing studies designed to characterize the mechanism by which the Epstein-Barr nuclear antigen 1 (EBNA-1) protein of Epstein-Barr virus (EBV) facilitates the stable replication of plasmids that bear oriP, EBV's plasmid origin of replication. Together my post-doctoral mentor, Dr. Bill Sugden, and I have demonstrated that oriP-plasmids are synthesized directly by the cell, and that EBNA-1 functions post- synthetically to stabilize oriP-plasmids. Our work also demonstrates that human cells can actively eliminate extra- chromosomal DNAs. This application experimentally addresses the process by which human cells eliminate plasmids, by defining when it occurs in the cell-cycle, and understanding the mechanism by which those viruses that maintain their genomes as plasmids in human cells overcome it. It also experimentally addresses the mechanism by which oriP-plasmids are stabilized so that they can be partitioned faithfully to daughter cells, and the contributions of EBNA-1 to these processes.
我将继续正在进行的研究,旨在描述 Epstein-Barr 病毒 (EBV) 的 Epstein-Barr 核抗原 1 (EBNA-1) 蛋白促进带有 oriP(EBV 的质粒复制起点)的质粒稳定复制的机制。 我和我的博士后导师 Bill Sugden 博士一起证明了 oriP 质粒是由细胞直接合成的,并且 EBNA-1 在合成后发挥作用以稳定 oriP 质粒。 我们的工作还表明,人类细胞可以主动消除染色体外的 DNA。 该应用程序通过定义质粒在细胞周期中发生的时间,并了解那些在人类细胞中以质粒形式维持其基因组的病毒克服质粒的机制,通过实验解决了人类细胞消除质粒的过程。 它还通过实验解决了 oriP 质粒稳定的机制,以便它们可以忠实地分配给子细胞,以及 EBNA-1 对这些过程的贡献。
项目成果
期刊论文数量(4)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
The use of CLUSTAL W and CLUSTAL X for multiple sequence alignment.
- DOI:10.1385/1-59259-192-2:221
- 发表时间:2000
- 期刊:
- 影响因子:0
- 作者:Ashok Aiyar
- 通讯作者:Ashok Aiyar
Cholesterol Supplementation During Production Increases the Infectivity of Retroviral and Lentiviral Vectors Pseudotyped with the Vesicular Stomatitis Virus Glycoprotein (VSV-G).
- DOI:10.1016/j.bej.2008.12.004
- 发表时间:2009-05-15
- 期刊:
- 影响因子:3.9
- 作者:Chen Y;Ott CJ;Townsend K;Subbaiah P;Aiyar A;Miller WM
- 通讯作者:Miller WM
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Ashok A Aiyar其他文献
Ashok A Aiyar的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Ashok A Aiyar', 18)}}的其他基金
Factors that modulate the deleterious effect of ammonia generation by chlamydial tryptophan synthase
调节衣原体色氨酸合酶产生氨有害作用的因素
- 批准号:
10198719 - 财政年份:2020
- 资助金额:
$ 14.89万 - 项目类别:
Factors that modulate the deleterious effect of ammonia generation by chlamydial tryptophan synthase
调节衣原体色氨酸合酶产生氨有害作用的因素
- 批准号:
10040215 - 财政年份:2020
- 资助金额:
$ 14.89万 - 项目类别:
Consequences of vaginal microbiota on IFNγ-mediated clearance of Chlamydia trachomatis
阴道微生物群对 IFNγ 介导的沙眼衣原体清除的影响
- 批准号:
9240286 - 财政年份:2017
- 资助金额:
$ 14.89万 - 项目类别:
Consequences of vaginal microbiota on IFNγ-mediated clearance of Chlamydia trachomatis
阴道微生物群对 IFNγ 介导的沙眼衣原体清除的影响
- 批准号:
9540785 - 财政年份:2017
- 资助金额:
$ 14.89万 - 项目类别:
NOVEL CELLULAR & GENETIC ANALYSES USING A NEW CHLAMYDIA PENETRANT PEPTIDE
新颖的蜂窝
- 批准号:
8166018 - 财政年份:2011
- 资助金额:
$ 14.89万 - 项目类别:
NOVEL CELLULAR & GENETIC ANALYSES USING A NEW CHLAMYDIA PENETRANT PEPTIDE
新颖的蜂窝
- 批准号:
8281426 - 财政年份:2011
- 资助金额:
$ 14.89万 - 项目类别:
Characterization and use of a novel AT-hook protein in Leishmania
利什曼原虫新型 AT-hook 蛋白的表征和应用
- 批准号:
8071117 - 财政年份:2010
- 资助金额:
$ 14.89万 - 项目类别:
Characterization and use of a novel AT-hook protein in Leishmania
利什曼原虫新型 AT-hook 蛋白的表征和应用
- 批准号:
7896108 - 财政年份:2010
- 资助金额:
$ 14.89万 - 项目类别:
Functions of EBNA1 in replication & partitioning of EBV
EBNA1 在复制中的功能
- 批准号:
7116680 - 财政年份:2005
- 资助金额:
$ 14.89万 - 项目类别:
Functions of EBNA1 in replication & partitioning of EBV
EBNA1 在复制中的功能
- 批准号:
6937180 - 财政年份:2005
- 资助金额:
$ 14.89万 - 项目类别:
相似海外基金
Elucidation of the life-sustaining mechanism of hyperthermophilic archaea without DNA replication origin
阐明无DNA复制起点的超嗜热古菌的生命维持机制
- 批准号:
19K22289 - 财政年份:2019
- 资助金额:
$ 14.89万 - 项目类别:
Grant-in-Aid for Challenging Research (Exploratory)
Identification of the DNA replication origin in Arabidopsis
拟南芥DNA复制起点的鉴定
- 批准号:
17K19250 - 财政年份:2017
- 资助金额:
$ 14.89万 - 项目类别:
Grant-in-Aid for Challenging Research (Exploratory)
Genome-wide identification of DNA replication origin sequences in human cells
人类细胞 DNA 复制起点序列的全基因组鉴定
- 批准号:
16K12595 - 财政年份:2016
- 资助金额:
$ 14.89万 - 项目类别:
Grant-in-Aid for Challenging Exploratory Research
Linking DNA Replication Origin Licensing with Cell Cycle Progression
将 DNA 复制起点许可与细胞周期进展联系起来
- 批准号:
8457662 - 财政年份:2013
- 资助金额:
$ 14.89万 - 项目类别:
Integrating stress MAP kinase signaling with DNA replication origin licensing
将应激 MAP 激酶信号传导与 DNA 复制起点许可相结合
- 批准号:
8706908 - 财政年份:2013
- 资助金额:
$ 14.89万 - 项目类别:
Linking DNA Replication Origin Licensing with Cell Cycle Progression
将 DNA 复制起点许可与细胞周期进展联系起来
- 批准号:
8665806 - 财政年份:2013
- 资助金额:
$ 14.89万 - 项目类别:
Integrating stress MAP kinase signaling with DNA replication origin licensing
将应激 MAP 激酶信号传导与 DNA 复制起点许可相结合
- 批准号:
8824650 - 财政年份:2013
- 资助金额:
$ 14.89万 - 项目类别:
Linking DNA Replication Origin Licensing with Cell Cycle Progression
将 DNA 复制起点许可与细胞周期进展联系起来
- 批准号:
8829782 - 财政年份:2013
- 资助金额:
$ 14.89万 - 项目类别:
Diversity Supplement: Post-Translational Regulation of DNA Replication Origin Licensing in Human Cells
多样性补充:人类细胞中 DNA 复制起点许可的翻译后调控
- 批准号:
10120875 - 财政年份:2013
- 资助金额:
$ 14.89万 - 项目类别:
Post-translational regulation of DNA replication origin licensing in human cells
人类细胞 DNA 复制起点许可的翻译后调控
- 批准号:
10093060 - 财政年份:2013
- 资助金额:
$ 14.89万 - 项目类别:














{{item.name}}会员




